1.Posar, A, Resca, F, Visconti, P. Autism according to diagnostic and statistical manual of mental disorders 5(th) edition: the need for further improvements. J Pediatr Neurosci. 2015;10(2):146–148.
2.Baio, J, Wiggins, L, Christensen, DL, et al. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR Surveill Summ. 2018;67(6):1–23.
3.Kent, JM, Kushner, S, Ning, XP, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord. 2013;43(8):1773–1783.
4.Owen, R, Sikich, L, Marcus, RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533–1540.
5.Fung, LK, Mahajan, R, Nozzolillo, A, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics. 2016;137:S124–S135.
6.Lord, C, Elsabbagh, M, Baird, G, Veenstra-Vanderweele, J. Autism spectrum disorder. Lancet. 2018;392(10146):508–520.
7.Buescher, AVS, Cidav, Z, Knapp, M, Mandell, DS Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014;168(8):721–728.
8.Jarbrink, K. The economic consequences of autistic spectrum disorder among children in a Swedish municipality. Autism. 2007;11(5):453–463.
9.Jarbrink, K, Fombonne, E, Knapp, M. Measuring the parental, service and cost impacts of children with autistic spectrum disorder: a pilot study. J Autism Dev Disord. 2003;33(4):395–402.
10.Cidav, Z, Marcus, SC, Mandell, DS Implications of childhood autism for parental employment and earnings. Pediatrics. 2012;129(4):617–623.
11.Howlin, P, Alcock, J, An, Burkin C. 8 year follow-up of a specialist supported employment service for high-ability adults with autism or Asperger syndrome. Autism. 2005;9(5):533–549.
12.Knapp, M, Romeo, R, Beecham, J. Economic cost of autism in the UK. Autism. 2009;13(3):317–336.
13.Peacock, G, Amendah, D, Ouyang, LJ, Grosse, SD Autism spectrum disorders and health care expenditures: the effects of co-occurring conditions. J Dev Behav Pediatr. 2012;33(1):2–8.
14.Modabbernia, A, Velthorst, E, Reichenberg, A. Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses. Mol Autism. 2017;8:13.
15.Liu, H, Talalay, P, Fahey, JW Biomarker-guided strategy for treatment of autism spectrum disorder (ASD). CNS Neurol Disord Drug Targets. 2016;15(5):602–613.
16.Petrelli, F, Pucci, L, Bezzi, P. Astrocytes and microglia and their potential link with autism spectrum disorders. Front Cell Neurosci. 2016;10:21.
17.Neniskyte, U, Gross, CT Errant gardeners: glial-cell-dependent synaptic pruning and neurodevelopmental disorders. Nat Rev Neurosci. 2017;18(11):658–670.
18.Schafer, DP, Stevens, B. Microglia function in central nervous system development and plasticity. CSH Perspect Biol. 2015;7(10):a020545.
19.Clarke, LE, Barres, BA Emerging roles of astrocytes in neural circuit development. Nat Rev Neurosci. 2013;14(5):311–321.
20.Harrison, JK, Jiang, Y, Chen, S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA. 1998;95(18):10896–10901.
21.Wu, Y, Dissing-Olesen, L, MacVicar, BA, Stevens, B. Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol. 2015;36(10):605–613.
22.Kakegawa, W, Mitakidis, N, Miura, E, et al. Anterograde C1ql1 signaling is required in order to determine and maintain a single-winner climbing fiber in the mouse cerebellum. Neuron. 2015;85(2):316–329.
23.Stevens, B, Allen, NJ, Vazquez, LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131(6):1164–1178.
24.Hong, S, Beja-Glasser, VF, Nfonoyim, BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712–716.
25.Halassa, MM, Fellin, T, Takano, H, Dong, JH, Haydon, PG Synaptic islands defined by the territory of a single astrocyte. J Neurosci. 2007;27(24):6473–6477.
26.Bushong, EA, Martone, ME, Jones, YZ, Ellisman, MH Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J Neurosci. 2002;22(1):183–192.
27.Chung, WS, Clarke, LE, Wang, GX, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504(7480):394–400.
28.Chung, WS, Verghese, PB, Chakraborty, C, et al. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci USA. 2016;113(36):10186–10191.
29.Bialas, AR, Stevens, B. TGF-beta signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci. 2013;16(12):1773–1782.
30.Yang, J, Yang, H, Liu, Y, et al. Astrocytes contribute to synapse elimination via type 2 inositol 1,4,5-trisphosphate receptor-dependent release of ATP. eLife. 2016;5:e15043.
31.Sipe, GO, Lowery, RL, Tremblay, ME, Kelly, EA, Lamantia, CE, Majewska, AK Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex. Nat Commun. 2016;7:10905.
32.Voineagu, I, Wang, XC, Johnston, P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474(7351):380.
33.Nardone, S, Sams, DS, Reuveni, E, et al. DNA methylation analysis of the autistic brain reveals multiple dysregulated biological pathways. Transl Psychiatry. 2014;4:e433.
34.Schafer, DP, Lehrman, EK, Kautzman, AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74(4):691–705.
35.Gehrmann, J, Matsumoto, Y, Kreutzberg, GW Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev. 1995;20(3):269–287.
36.Lan, X, Han, X, Li, Q, Yang, QW, Wang, J. Modulators of microglial activation and polarization after intracerebral haemorrhage. Nat Rev Neurol. 2017;13(7):420–433.
37.Lenz, KM, Nelson, LH Microglia and beyond: innate immune cells as regulators of brain development and behavioral function. Front Immunol. 2018;9:698.
38.Barbierato, M, Facci, L, Argentini, C, Marinelli, C, Skaper, SD, Giusti, P. Astrocyte-microglia cooperation in the expression of a pro-inflammatory phenotype. CNS Neurol Disord Drug Targets. 2013;12(5):608–618.
39.Kofler, J, Wiley, CA Microglia: key innate immune cells of the brain. Toxicol Pathol. 2011;39(1):103–114.
40.Young, AM, Chakrabarti, B, Roberts, D, Lai, MC, Suckling, J, Baron-Cohen, S. From molecules to neural morphology: understanding neuroinflammation in autism spectrum condition. Mol Autism. 2016;7:9.
41.Vargas, DL, Nascimbene, C, Krishnan, C, Zimmerman, AW, Pardo, CA Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57(1):67–81.
42.Morgan, JT, Chana, G, Abramson, I, Semendeferi, K, Courchesne, E, Everall, IP Abnormal microglial-neuronal spatial organization in the dorsolateral prefrontal cortex in autism. Brain Res. 2012;1456:72–81.
43.Tetreault, NA, Hakeem, AY, Jiang, S, et al. Microglia in the cerebral cortex in autism. J Autism Dev Disord. 2012;42(12):2569–2584.
44.Edmonson, C, Ziats, MN, Rennert, OM Altered glial marker expression in autistic post-mortem prefrontal cortex and cerebellum. Mol Autism. 2014;5(1):3.
45.Suzuki, K, Sugihara, G, Ouchi, Y, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry. 2013;70(1):49–58.
46.Li, X, Chauhan, A, Sheikh, AM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol. 2009;207(1–2):111–116.
47.Wei, H, Zou, H, Sheikh, AM, et al. IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J Neuroinflam. 2011;8:52.
48.Estes, ML, McAllister, AK Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat Rev Neurosci. 2015;16(8):469–486.
49.Masi, A, Breen, EJ, Alvares, GA, et al. Cytokine levels and associations with symptom severity in male and female children with autism spectrum disorder. Mol Autism. 2017;8:63.
50.Ricci, S, Businaro, R, Ippoliti, F, et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox Res. 2013;24(4):491–501.
51.Molloy, CA, Morrow, AL, Meinzen-Derr, J, et al. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol. 2006;172(1–2):198–205.
52.Suzuki, K, Matsuzaki, H, Iwata, K, et al. Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PLoS One. 2011;6(5):e20470.
53.Jiang, HY, Xu, LL, Shao, L, et al. Maternal infection during pregnancy and risk of autism spectrum disorders: a systematic review and meta-analysis. Brain Behav Immunity. 2016;58:165–172.
54.Dachew, BA, Mamun, A, Maravilla, JC, Alati, R. Pre-eclampsia and the risk of autism-spectrum disorder in offspring: meta-analysis. Br J Psychiatry. 2018;212(3):142–147.
55.Xu, G, Jing, J, Bowers, K, Liu, B, Bao, W. Maternal diabetes and the risk of autism spectrum disorders in the offspring: a systematic review and meta-analysis. J Autism Dev Disord. 2014;44(4):766–775.
56.Li, YM, Ou, JJ, Liu, L, Zhang, D, Zhao, JP, Tang, SY Association between maternal obesity and autism spectrum disorder in offspring: a meta-analysis. J Autism Dev Disord. 2016;46(1):95–102.
57.Chen, SW, Zhong, XS, Jiang, LN, et al. Maternal autoimmune diseases and the risk of autism spectrum disorders in offspring: a systematic review and meta-analysis. Behav Brain Res. 2016;296:61–69.
58.Marques, AH, O’Connor, TG, Roth, C, Susser, E, Bjorke-Monsen, AL The influence of maternal prenatal and early childhood nutrition and maternal prenatal stress on offspring immune system development and neurodevelopmental disorders. Front Neurosci. 2013;7:120.
59.Kim, KC, Gonzales, EL, Lazaro, MT, et al. Clinical and neurobiological relevance of current animal models of autism spectrum disorders. Biomol Therap. 2016;24(3):207–243.
60.Knuesel, I, Chicha, L, Britschgi, M, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol. 2014;10(11):643–660.
61.Estes, ML, McAllister, AK Maternal immune activation: implications for neuropsychiatric disorders. Science. 2016;353(6301):772–777.
62.Smith, SE, Li, J, Garbett, K, Mirnics, K, Patterson, PH Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007;27(40):10695–10702.
63.Hsiao, EY, Patterson, PH Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav Immunity. 2011;25(4):604–615.
64.Graham, AM, Rasmussen, JM, Rudolph, MD, et al. Maternal systemic interleukin-6 during pregnancy is associated with newborn amygdala phenotypes and subsequent behavior at 2 years of age. Biol Psychiatry. 2018;83(2):109–119.
65.Magni, P, Ruscica, M, Dozio, E, Rizzi, E, Beretta, G, Maffei Facino, R. Parthenolide inhibits the LPS-induced secretion of IL-6 and TNF-alpha and NF-kappaB nuclear translocation in BV-2 microglia. Phytother Res. 2012;26(9):1405–1409.
66.Nakanishi, M, Niidome, T, Matsuda, S, Akaike, A, Kihara, T, Sugimoto, H. Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells. Eur J Neurosci. 2007;25(3):649–658.
67.Almolda, B, Villacampa, N, Manders, P, et al. Effects of astrocyte-targeted production of interleukin-6 in the mouse on the host response to nerve injury. Glia. 2014;62(7):1142–1161.
68.Penkowa, M, Camats, J, Hadberg, H, et al. Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide. J Neurosci Res. 2003;73(4):481–496.
69.Riccomagno, MM, Kolodkin, AL Sculpting neural circuits by axon and dendrite pruning. Annu Rev Cell Dev Biol. 2015;31:779–805.
70.Darabid, H, Arbour, D, Robitaille, R. Glial cells decipher synaptic competition at the mammalian neuromuscular junction. J Neurosci. 2013;33(4):1297–1313.
71.Zhan, Y, Paolicelli, RC, Sforazzini, F, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci. 2014;17(3):400–406.
72.Dinstein, I, Pierce, K, Eyler, L, et al. Disrupted neural synchronization in toddlers with autism. Neuron. 2011;70(6):1218–1225.
73.Dichter, GS Functional magnetic resonance imaging of autism spectrum disorders. Dialog Clin Neurosci. 2012;14(3):319–351.
74.Barttfeld, P, Wicker, B, Cukier, S, Navarta, S, Lew, S, Sigman, M. A big-world network in ASD: dynamical connectivity analysis reflects a deficit in long-range connections and an excess of short-range connections. Neuropsychologia. 2011;49(2):254–263.
75.Tang, GM, Gudsnuk, K, Kuo, SH, et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron. 2014;83(5):1131–1143.
76.Hutsler, JJ, Zhang, H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res. 2010;1309:83–94.
77.Piochon, C, Kloth, AD, Grasselli, G, et al. Cerebellar plasticity and motor learning deficits in a copy-number variation mouse model of autism. Nat Commun. 2015;5:5586.
78.Kim, HJ, Cho, MH, Shim, WH, et al. Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects. Mol Psychiatry. 2017;22(11):1576–1584.
79.Paolicelli, RC, Bolasco, G, Pagani, F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333(6048):1456–1458.
80.Itoh, K, Wakabayashi, N, Katoh, Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13(1):76–86.
81.Ma, Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426.
82.Shih, RH, Wang, CY, Yang, CM NF-kappaB signaling pathways in neurological inflammation: a mini review. Front Mol Neurosci. 2015;8:77.
83.Matsushima, A, Kaisho, T, Rennert, PD, et al. Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. J Exp Med. 2001;193(5):631–636.
84.Gupta, SC, Sundaram, C, Reuter, S, Aggarwal, BB Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 2010;1799(10–12):775–787.
85.Nair, S, Doh, ST, Chan, JY, Kong, AN, Cai, L. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer. 2008;99(12):2070–2082.
86.Liu, GH, Qu, J, Shen, X. NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim Biophys Acta. 2008;1783(5):713–727.
87.Yu, MA, Li, H, Liu, QM, et al. Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway. Cell Signal. 2011;23(5):883–892.
88.Kim, JE, You, DJ, Lee, C, Ahn, C, Seong, JY, Hwang, JI Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. Cell Signal. 2010;22(11):1645–1654.
89.Innamorato, NG, Rojo, AI, Garcia-Yague, AJ, Yamamoto, M, de Ceballos, ML, Cuadrado, A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol. 2008;181(1):680–689.
90.Ho, FM, Kang, HC, Lee, ST, et al. The anti-inflammatory actions of LCY-2-CHO, a carbazole analogue, in vascular smooth muscle cells. Biochem Pharmacol. 2007;74(2):298–308.
91.Lee, HJ, Macbeth, AH, Pagani, JH, Young, WS Oxytocin: the great facilitator of life. Prog Neurobiol. 2009;88(2):127–151.
92.Guastella, AJ, Hickie, IB Oxytocin Treatment, circuitry, and autism: a critical review of the literature placing oxytocin into the autism context. Biol Psychiatry. 2016;79(3):234–242.
93.Wagner, S, Harony-Nicolas, H. Oxytocin and animal models for autism spectrum disorder. Curr Top Behav Neurosci. 2018;35:213–237.
94.Anagnostou, E, Soorya, L, Chaplin, W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012;3(1):16.
95.Andari, E, Duhamel, JR, Zalla, T, Herbrecht, E, Leboyer, M, Sirigu, A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci USA. 2010;107(9):4389–4394.
96.Auyeung, B, Lombardo, MV, Heinrichs, M, et al. Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism. Transl Psychiatry. 2015;5:e507.
97.Dadds, MR, MacDonald, E, Cauchi, A, Williams, K, Levy, F, Brennan, J. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord. 2014;44(3):521–531.
98.Domes, G, Heinrichs, M, Kumbier, E, Grossmann, A, Hauenstein, K, Herpertz, SC Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biol Psychiatry. 2013;74(3):164–171.
99.Watanabe, T, Abe, O, Kuwabara, H, et al. Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial. JAMA Psychiatry. 2014;71(2):166–175.
100.Gordon, I, Vander Wyk, BC, Bennett, RH, et al. Oxytocin enhances brain function in children with autism. Proc Natl Acad Sci USA. 2013;110(52):20953–20958.
101.Guastella, AJ, Einfeld, SL, Gray, KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67(7):692–694.
102.Guastella, AJ, Gray, KM, Rinehart, NJ, et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry Allied Disc. 2015;56(4):444–452.
103.Yatawara, CJ, Einfeld, SL, Hickie, IB, Davenport, TA, Guastella, AJ The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry. 2016;21(9):1225–1231.
104.Yamasue, H, Okada, T, Munesue, T, et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Mol Psychiatry. 2018. doi: 10.1038/s41380-018-0097-2.
105.Munesue, T, Nakamura, H, Kikuchi, M, et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Front Psychiatry. 2016;7:2.
106.Kosaka, H, Okamoto, Y, Munesue, T, et al. Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial. Transl Psychiatry. 2016;6(8):e872.
107.Rajamani, KT, Wagner, S, Grinevich, V, Harony-Nicolas, H. Oxytocin as a modulator of synaptic plasticity: implications for neurodevelopmental disorders. Front Synaptic Neurosci. 2018;10:17.
108.Bakos, J, Srancikova, A, Havranek, T, Bacova, Z. Molecular mechanisms of oxytocin signaling at the synaptic connection. Neural Plasticity. 2018;2018:4864107.
109.van den Pol, AN. Neuropeptide transmission in brain circuits. Neuron. 2012;76(1):98–115.
110.Yuan, L, Liu, S, Bai, X, et al. Oxytocin inhibits lipopolysaccharide-induced inflammation in microglial cells and attenuates microglial activation in lipopolysaccharide-treated mice. J Neuroinflam. 2016;13(1):77.
111.Wang, Y, Zhao, S, Liu, X, Zheng, Y, Li, L, Meng, S. Oxytocin improves animal behaviors and ameliorates oxidative stress and inflammation in autistic mice. Biomed Pharmacother. 2018;107:262–269.
112.Wang, T, Shan, L, Du, L, et al. Serum concentration of 25-hydroxyvitamin D in autism spectrum disorder: a systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2016;25(4):341–350.
113.Fernell, E, Bejerot, S, Westerlund, J, et al. Autism spectrum disorder and low vitamin D at birth: a sibling control study. Mol Autism. 2015;6:3.
114.Kerley, CP, Power, C, Gallagher, L, Coghlan, D. Lack of effect of vitamin D3 supplementation in autism: a 20-week, placebo-controlled RCT. Arch Dis Childh. 2017;102(11):1030–1036.
115.Bent, S, Ailarov, A, Dang, KT, Widjaja, F, Lawton, BL, Hendren, RL Open-label trial of vitamin D3 supplementation in children with autism spectrum disorder. J Alternat Complement Med. 2017;23(5):394–395.
116.Feng, J, Shan, L, Du, L, et al. Clinical improvement following vitamin D3 supplementation in autism spectrum disorder. Nutr Neurosci. 2017;20(5):284–290.
117.Jia, F, Shan, L, Wang, B, et al. Fluctuations in clinical symptoms with changes in serum 25(OH) vitamin D levels in autistic children: three cases report. Nutr Neurosci. 2018:1–4. doi: 10.1080/1028415X.2018.1458421
118.Jia, F, Wang, B, Shan, L, Xu, Z, Staal, WG, Du, L. Core symptoms of autism improved after vitamin D supplementation. Pediatrics. 2015;135(1):e196–e198.
119.Cannell, JJ Vitamin D and autism, what’s new? Rev Endocr Metab Disord. 2017;18(2):183–193.
120.Huang, YN, Ho, YJ, Lai, CC, Chiu, CT, Wang, JY 1,25-Dihydroxyvitamin D3 attenuates endotoxin-induced production of inflammatory mediators by inhibiting MAPK activation in primary cortical neuron-glia cultures. J Neuroinflam. 2015;12:147.
121.Nakai, K, Fujii, H, Kono, K, et al. Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats. Am J Hypertens. 2014;27(4):586–595.
122.Eyles, DW, Burne, TH, McGrath, JJ Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013;34(1):47–64.
123.Grecksch, G, Ruthrich, H, Hollt, V, Becker, A. Transient prenatal vitamin D deficiency is associated with changes of synaptic plasticity in the dentate gyrus in adult rats. Psychoneuroendocrinology. 2009;34(Suppl 1):S258–S264.
124.Latimer, CS, Brewer, LD, Searcy, JL, et al. Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc Natl Acad Sci USA. 2014;111(41):E4359–E4366.
125.Fernandes de Abreu, DA, Nivet, E, Baril, N, Khrestchatisky, M, Roman, F, Feron, F. Developmental vitamin D deficiency alters learning in C57Bl/6J mice. Behav Brain Res. 2010;208(2):603–608.
126.Tarozzi, A, Angeloni, C, Malaguti, M, Morroni, F, Hrelia, S, Hrelia, P. ulforaphane as a potential protective phytochemical against neurodegenerative diseases. Oxidat Med Cell Long. 2013;2013:415078.
127.Benedict, AL, Mountney, A, Hurtado, A, et al. Neuroprotective effects of sulforaphane after contusive spinal cord injury. J Neurotr. 2012;29(16):2576–2586.
128.Carrasco-Pozo, C, Tan, KN, Borges, K. Sulforaphane is anticonvulsant and improves mitochondrial function. J Neurochem. 2015;135(5):932–942.
129.Singh, K, Connors, SL, Macklin, EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci USA. 2014;111(43):15550–15555.
130.Bent, S, Lawton, B, Warren, T, et al. Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. Mol Autism. 2018;9:35.
131.Jang, M, Cho, IH Sulforaphane ameliorates 3-nitropropionic acid-induced striatal toxicity by activating the Keap1-Nrf2-ARE pathway and inhibiting the MAPKs and NF-kappaB pathways. Mol Neurobiol. 2016;53(4):2619–2635.
132.Jazwa, A, Rojo, AI, Innamorato, NG, Hesse, M, Fernandez-Ruiz, J, Cuadrado, A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal. 2011;14(12):2347–2360.
133.Liu, H, Dinkova-Kostova, AT, Talalay, P. Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc Natl Acad Sci USA. 2008;105(41):15926–15931.
134.Jeong, WS, Kim, IW, Hu, R, Kong, AN Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res. 2004;21(4):661–670.
135.Heiss, E, Herhaus, C, Klimo, K, Bartsch, H, Gerhauser, C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem. 2001;276(34):32008–32015.
136.Holloway, PM, Gillespie, S, Becker, F, et al. Sulforaphane induces neurovascular protection against a systemic inflammatory challenge via both Nrf2-dependent and independent pathways. Vasc Pharmacol. 2016;85:29–38.
137.Pawlik, A, Wiczk, A, Kaczynska, A, Antosiewicz, J, Herman-Antosiewicz, A. Sulforaphane inhibits growth of phenotypically different breast cancer cells. Eur J Nutr. 2013;52(8):1949–1958.
138.Jo, C, Kim, S, Cho, SJ, et al. Sulforaphane induces autophagy through ERK activation in neuronal cells. FEBS Lett. 2014;588(17):3081–3088.
139.Liu, Y, Hettinger, CL, Zhang, D, Rezvani, K, Wang, X, Wang, H. Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington’s disease. J Neurochem. 2014;129(3):539–547.
140.Gambini, J, Ingles, M, Olaso, G, et al. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Long. 2015;2015:837042.
141.Novelle, MG, Wahl, D, Dieguez, C, Bernier, M, de Cabo, R. Resveratrol supplementation: where are we now and where should we go? Ageing Res Rev. 2015;21:1–15.
142.Bhandari, R, Kuhad, A. Resveratrol suppresses neuroinflammation in the experimental paradigm of autism spectrum disorders. Neurochem Int. 2017;103:8–23.
143.Bambini-Junior, V, Zanatta, G, Della Flora Nunes, G, et al. Resveratrol prevents social deficits in animal model of autism induced by valproic acid. Neurosci Lett. 2014;583:176–181.
144de Sa Coutinho, D, Pacheco, MT, Frozza, RL, Bernardi, A. Anti-inflammatory effects of resveratrol: mechanistic insights. Int J Mol Sci. 2018;19(6):e1812.
145.Elshaer, M, Chen, Y, Wang, XJ, Tang, X. Resveratrol: an overview of its anti-cancer mechanisms. Life Sci. 2018;207:340–349.
146.Yang, X, Xu, S, Qian, Y, Xiao, Q. Resveratrol regulates microglia M1/M2 polarization via PGC-1alpha in conditions of neuroinflammatory injury. Brain Behav Immun. 2017;64:162–172.
147.Truong, VL, Jun, M, Jeong, WS Role of resveratrol in regulation of cellular defense systems against oxidative stress. BioFactors. 2018;44(1):36–49.
148.Cianciulli, A, Calvello, R, Cavallo, P, Dragone, T, Carofiglio, V, Panaro, MA Modulation of NF-kappaB activation by resveratrol in LPS treated human intestinal cells results in downregulation of PGE2 production and COX-2 expression. Toxicol In Vitro. 2012;26(7):1122–1128.
149.Li, H, Wang, J, Wang, P, Rao, Y, Chen, L. Resveratrol reverses the synaptic plasticity deficits in a chronic cerebral hypoperfusion rat model. J Stroke Cerebrovasc Dis. 2016;25(1):122–128.
150.Quincozes-Santos, A, Gottfried, C. Resveratrol modulates astroglial functions: neuroprotective hypothesis. Ann NY Acad Sci. 2011;1215:72–78.